AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Does Inhibiting PCS K9 Make a Difference?
Fourier and odyssey were trials that looked at two pc s k nine inhibitors. Fourier took patients with an average l d l calestral of something like 90 or 92 milligrams per decileter. These patients were already on the maximum tolerated dose of a staton, ok? And in two point two years, showed a reduction in events. The null hypothesis should be, it should have never worked. You should have needed 20 years to show any benefit when you understand allan snyderman's lifetime exposure model.